ExoVasc® PEARS

Royal Brompton Hospital approves device

Following the completion of the initial clinical trial the Clinical Practice Committee at the Royal Brompton Hospital has approved the device for use in the treatment of suitable patients with a dilated aorta due to Marfan syndrome.

A new, innovative procedure is a big step forward for patients with an enlarged aorta

Exstent Appoints Matt Thompson as CEO to Drive Global Growth in Personalised Aortic Support

Interested in our patient experiences?

We develop medical devices that manage aortic dilatation and minimise the risk of aortic dissection.

quick links

statements & policies

Our contact details

The staff of Exstent Limited are not medically qualified and are thus not able to provide clinical advice or answer questions of a clinical nature. We may direct your attention to publications in peer-reviewed journals that provide clinical information or provide information based upon personal experience. However, for any questions of a clinical nature patients are recommended to consult a qualified clinician.